EQ - Equillium, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Equillium, Inc.

2223 Avenida De La Playa
Suite 105 La Jolla
San Diego, CA 92037
United States
858-412-5302
http://www.equilliumbio.com

Sector
Industry
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel Mark BradburyCEO & Chairman315kN/A1961
Dr. Stephen ConnellyChief Scientific Officer & Director373.75kN/A1982
Dr. Krishna R. PoluChief Medical Officer419.75kN/A1973
Mr. Bruce D. Steel C.F.A.Co-Founder, Pres, Chief Bus. Officer & DirectorN/AN/A1966
Mr. Jason A. KeyesChief Financial OfficerN/AN/A1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Corporate Governance

Equillium, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.